Cancer Immunology, Immunotherapy

, Volume 52, Issue 10, pp 638–642

Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients

  • L. G. Durrant
  • M. A. Chapman
  • D. J. Buckley
  • I. Spendlove
  • R. A. Robins
  • N. C. Armitage
Original Article

DOI: 10.1007/s00262-003-0402-y

Cite this article as:
Durrant, L.G., Chapman, M.A., Buckley, D.J. et al. Cancer Immunol Immunother (2003) 52: 638. doi:10.1007/s00262-003-0402-y

Abstract

This study prospectively correlated the level of expression of CD55 on tumours with 7-year survival in 136 colorectal cancer patients. Patients with tumours expressing high levels of CD55 had a significantly worse survival (24%) than patients with low CD55 levels (50%, p<0.02). A similar difference was seen for patients (Duke's B or C) with a high risk of recurrence (29% vs 58%, p<0.05). Furthermore, there was a progressive deterioration in prognosis with increasing antigen expression (p=0.01). It remains unclear if CD55 is overexpressed by tumours to protect them from complement or if it is related to the recent observation that CD55 is a ligand for the T-cell activation antigen CD97. However, it is a marker of aggression, as colorectal cancer patients whose tumours overexpress CD55 have a significantly reduced 7-year survival.

Keywords

Prognostic factor Colorectal cancer 

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • L. G. Durrant
    • 1
  • M. A. Chapman
    • 2
  • D. J. Buckley
    • 2
  • I. Spendlove
    • 1
  • R. A. Robins
    • 3
  • N. C. Armitage
    • 2
  1. 1.CRC Academic Department of Clinical OncologyCity HospitalNottinghamUK
  2. 2.Department of SurgeryUniversity of NottinghamNottinghamUK
  3. 3.Department of ImmunologyUniversity of NottinghamNottinghamUK

Personalised recommendations